H.C. Wainwright analyst Swayampakula Ramakanth has reiterated their bullish stance on ABSI stock, giving a Buy rating on April 17.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Swayampakula Ramakanth has given his Buy rating due to a combination of factors tied to AbSci’s emerging hair-loss program and valuation upside. He notes that recent data from a competing oral minoxidil product have effectively set a new efficacy standard in pattern hair loss, and he believes ABS-201 can surpass this bar if it achieves a hair-count gain above 40 hairs/cm² with favorable safety outcomes.
Ramakanth also highlights that ABS-201’s anticipated dosing every two to three months by subcutaneous injection could offer a notable convenience and potential safety edge over daily oral regimens. In his valuation work, he applies a risk‑adjusted discounted cash flow framework to AbSci’s partnered pipeline, adds the company’s sizable net cash, and arrives at an intrinsic value that supports a $8.00 per share target, leading him to reiterate a Buy recommendation.
In another report released on April 17, Needham also assigned a Buy rating to the stock with a $7.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABSI in relation to earlier this year.